PE-22-28
PE-22-28 is a short synthetic peptide studied in early-stage work on mood-related behaviour. Its development is linked to spadin, a peptide investigated for effects on the TREK-1 potassium channel.
Evidence is predominantly preclinical and growing. PE-22-28 is considered only alongside psychiatric care and prescribed treatment, under physician supervision.
What Is PE-22-28?
PE-22-28 is a seven-amino-acid peptide developed from work on shorter spadin-related sequences. It belongs to an experimental programme examining neuronal potassium-channel activity.
Its designation identifies an experimental molecule, not a clinically validated treatment or a standardised consumer product.
How Does PE-22-28 Work?
Laboratory studies report inhibition of TREK-1, a potassium channel that helps regulate neuronal electrical activity. This channel has been investigated as a possible target in mood disorders.
Channel effects depend on experimental conditions, and research into mood-related applications continues.
What Has Research Studied?
Published work has examined channel activity, peptide stability and behaviour in animal models used to explore antidepressant-like effects.
Related sortilin-derived peptides have also been studied in mouse models of stroke and post-stroke mood changes. These findings inform ongoing research into PE-22-28.
Safety and Medical Supervision
A physician assessment reviews tolerability, interactions and monitoring needs before any protocol.
Depression requires appropriate assessment and evidence-based care. Any new option is considered under physician supervision, and psychiatric medicines are only adjusted with the prescribing clinician.
Frequently Asked Questions
Is PE-22-28 an approved antidepressant?
It is not an established approved antidepressant. Its evidence base remains at an early experimental stage.
Do animal behavioural tests prove it treats depression?
Such tests explore biological hypotheses and guide ongoing clinical research.
Is PE-22-28 the same as every spadin analogue?
Related peptides may differ in structure, stability and biological activity, so a physician matches the evidence to the exact molecule.
Can it replace prescribed antidepressants?
It is considered alongside prescribed medicines, psychological therapy and psychiatric follow-up.
References
- Frontiers in Pharmacology via PubMed. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
- Neuropharmacology via PubMed. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides
- NHS. Clinical trials
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Related Peptides
Wondering Whether PE-22-28 Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.